ILC2s, dependent on the GATA-binding protein 3 (GATA3) transcription factor for development, exert anti-tumor activity by secreting type 2 cytokines such as IL-4 and IL-13 in the tumor microenvironment, influencing tumor prognosis (158). This evidence concerns the gene GATA3 and neoplasm.